ADVENZYMES Advanced Enzyme Technologies Q3 FY26 results (Oct–Dec 2025) and concall
Advanced Enzyme Technologies reported mixed results for Q3 FY26, with modest 2% Y-o-Y revenue growth and an 11% decline in EBITDA, primarily due to weakness in the Human Healthcare segment. While Animal Healthcare and Bioprocessing showed strong growth, the overall performance was impacted by US market uncertainties and tariff effects. The company remains optimistic about long-term growth, driven by strategic R&D investments and expansion into new areas like B2C and biocatalysis.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 5.0%, net profit down 13.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 77 | 101 | 87 | 125 | 116 +51% | 96 −5% |
| EBITDA | 14 | 22 | 14 | 31 | 30 +114% | 23 +5% |
| Net profit | 9 | 15 | 11 | 74 | 22 +144% | 13 −13% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
